Monday - April 14, 2025
SOMERSET, N.J., May 09, 2023 (GLOBE NEWSWIRE) -- CareCloud, Inc. (Nasdaq: CCLD, CCLDP, CCLDO), a leader in healthcare technology solutions for medical practices and health systems nationwide, announced today that Bill Korn, chief strategy officer, and Joseph DosSantos, chief financial officer, will be available to meet with investors and discuss CareCloud's strategy and financial performance at several upcoming healthcare conferences.
To arrange a meeting with Bill and Joe, investors can contact Bridget Forde at CareCloudIR@westwicke.com.
About CareCloud
CareCloud (Nasdaq: CCLD, CCLDP, CCLDO) brings disciplined innovation to the business of healthcare. Our suite of technology-enabled solutions helps clients increase financial and operational performance, streamline clinical workflows and improve the patient experience. More than 40,000 providers count on CareCloud to help them improve patient care while reducing administrative burdens and operating costs. Learn more about our products and services, including revenue cycle management (RCM), practice management (PM), electronic health records (EHR), business intelligence, patient experience management (PXM) and digital health, at www.carecloud.com.
Follow CareCloud on LinkedIn, Twitter and Facebook.
SOURCE CareCloud
Company Contact:
Bill Korn
Chief Strategy Officer
CareCloud
bkorn@carecloud.com
Investor Contact:
Asher Dewhurst
ICR Westwicke
CareCloudIR@westwicke.com
Media Inquiries:
Alexis Feinberg
ICR Westwicke
CareCloudPR@westwicke.com
Last Trade: | US$1.34 |
Daily Change: | 0.15 12.61 |
Daily Volume: | 539,065 |
Market Cap: | US$21.790M |
April 07, 2025 April 02, 2025 March 26, 2025 March 13, 2025 January 28, 2025 |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load